IBB News & Analysis

IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions

The iShares Biotechnology ETF (IBB) has risen 51% over the last year and is up 16.06% year to date, compared to a 9.22% gain for the S&P 500. Eli Lilly (LLY) has announced four acquisitions in Q1 2026 and reported Q1 revenues of $19.80 billion, a 55.5% increase year over year. The company's Mounjaro revenue reached $8.66 billion, a 125% growth. Cramer expects an influx of deals in the biotech sector following changes in FDA leadership, making biotech an attractive sector for investors given current market conditions.